Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Fennec Pharmaceuticals (FENC) Other Non Operating Income: 2011-2025

Historic Other Non Operating Income for Fennec Pharmaceuticals (FENC) over the last 12 years, with Sep 2025 value amounting to -$3,000.

  • Fennec Pharmaceuticals' Other Non Operating Income was N/A to -$3,000 in Q3 2025 from the same period last year, while for Jun 2025 it was -$14,000, marking a year-over-year increase of 78.12%. This contributed to the annual value of -$82,000 for FY2024, which is 1740.00% down from last year.
  • Per Fennec Pharmaceuticals' latest filing, its Other Non Operating Income stood at -$3,000 for Q3 2025, which was down 117.65% from $17,000 recorded in Q2 2025.
  • Over the past 5 years, Fennec Pharmaceuticals' Other Non Operating Income peaked at $17,000 during Q2 2025, and registered a low of -$38,000 during Q1 2024.
  • Over the past 3 years, Fennec Pharmaceuticals' median Other Non Operating Income value was -$500 (recorded in 2023), while the average stood at -$5,000.
  • Per our database at Business Quant, Fennec Pharmaceuticals' Other Non Operating Income skyrocketed by 400.00% in 2023 and then tumbled by 1,450.00% in 2024.
  • Over the past 5 years, Fennec Pharmaceuticals' Other Non Operating Income (Quarterly) stood at -$1,000 in 2021, then plummeted by 300.00% to -$4,000 in 2022, then crashed by 175.00% to $2,000 in 2023, then crashed by 1,450.00% to -$27,000 in 2024, then surged by 200.00% to -$3,000 in 2025.
  • Its last three reported values are -$3,000 in Q3 2025, $17,000 for Q2 2025, and $13,000 during Q1 2025.